This is the authors' abstract. We don't add key points for this paper.
Severe or life-threatening chimeric antigen receptor (CAR) T cell-induced cytokine release syndrome (CRS) requires urgent treatment to prevent fatal outcomes. In two independent cohorts, the majority of patients with severe or life-threatening CAR T cell-induced CRS responded to treatment with one or two doses of tocilizumab in addition to advanced supportive care. More research is needed to determine the optimal dose and schedule of tocilizumab for treatment of CAR T cell-induced CRS.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Le et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: